{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:01:16Z","timestamp":1773270076939,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s12325-021-01721-x","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T23:06:04Z","timestamp":1619737564000},"page":"3455-3464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Chlormethine Gel in Combination with Other Therapies in the Treatment of Patients with Mycosis Fungoides Cutaneous T\u00a0Cell Lymphoma: Three Case Reports"],"prefix":"10.1007","volume":"38","author":[{"given":"Kyriaki","family":"Lampadaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marios","family":"Koumourtzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fani","family":"Karagianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonidas","family":"Marinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"key":"1721_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703\u201314.","journal-title":"Blood"},{"key":"1721_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.clindermatol.2019.01.004","volume":"37","author":"E Hodak","year":"2019","unstructured":"Hodak E, Amitay-Laish I. Mycosis fungoides: a great imitator. Clin Dermatol. 2019;37:255\u201367.","journal-title":"Clin Dermatol"},{"key":"1721_CR3","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1182\/blood.V88.7.2385.bloodjournal8872385","volume":"88","author":"E Diamandidou","year":"1996","unstructured":"Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood. 1996;88:2385\u2013409.","journal-title":"Blood"},{"key":"1721_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1365-2133.2008.08992.x","volume":"160","author":"F Sampogna","year":"2009","unstructured":"Sampogna F, Frontani M, Baliva G, et al. Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol. 2009;160:815\u201322.","journal-title":"Br J Dermatol"},{"key":"1721_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/annonc\/mdy133","volume":"29","author":"R Willemze","year":"2018","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:30\u201340.","journal-title":"Ann Oncol"},{"key":"1721_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update 2017. Eur J Cancer. 2017;77:57\u201374.","journal-title":"Eur J Cancer"},{"key":"1721_CR7","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Primary cutaneous lymphomas. Version 1. 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/default_nojava.aspx. Accessed Dec 4 2020"},{"key":"1721_CR8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3389\/fonc.2019.00260","volume":"9","author":"ES Tarabadkar","year":"2019","unstructured":"Tarabadkar ES, Shinohara MM. Skin directed therapy in cutaneous T-cell lymphoma. Front Oncol. 2019;9:260.","journal-title":"Front Oncol"},{"key":"1721_CR9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","volume":"20","author":"EC Vonderheid","year":"1989","unstructured":"Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol. 1989;20:416\u201328.","journal-title":"J Am Acad Dermatol"},{"key":"1721_CR10","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S0889-8588(18)30057-1","volume":"9","author":"DL Ramsay","year":"1995","unstructured":"Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin N Am. 1995;9:1031\u201356.","journal-title":"Hematol Oncol Clin N Am"},{"key":"1721_CR11","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.jdcr.2020.05.031","volume":"6","author":"ES Gilmore","year":"2020","unstructured":"Gilmore ES, Alexander-Savino CV, Chung CG, Poligone B. Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis. JAAD Case Rep. 2020;6:878\u201381.","journal-title":"JAAD Case Rep"},{"key":"1721_CR12","unstructured":"Valchlor (mechlorethamine) gel [prescribing information]. Iselin, NJ: Helsinn Therapeutics (U.S.), Inc.; 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202317s009lbl.pdf. Accessed 19 Jan 2021"},{"key":"1721_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","volume":"149","author":"SR Lessin","year":"2013","unstructured":"Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149:25\u201332.","journal-title":"JAMA Dermatol"},{"key":"1721_CR14","doi-asserted-by":"publisher","first-page":"9093","DOI":"10.1200\/jco.2014.32.15_suppl.9093","volume":"32","author":"YH Kim","year":"2014","unstructured":"Kim YH, Duvic M, Guitart J, Lessin S. Efficacy and safety of mechlorethamine (MCH) 0.04% gel in mycosis fungoides (MF) after treatment with topical MCH 0.02%. J Clin Oncol. 2014;32:9093.","journal-title":"J Clin Oncol"},{"key":"1721_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1586\/17512433.2014.944500","volume":"7","author":"R Talpur","year":"2014","unstructured":"Talpur R, Venkatarajan S, Duvic M. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma. Expert Rev Clin Pharmacol. 2014;7:591\u20137.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1721_CR16","unstructured":"Ledaga [summary of product characteristics]. Dublin, Ireland: Helsinn Pharmaceuticals Ltd.; 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ledaga-epar-product-information_en.pdf. Accessed 19 Jan 2021"},{"key":"1721_CR17","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"EA Olsen","year":"2011","unstructured":"Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29:2598\u2013607.","journal-title":"J Clin Oncol"},{"key":"1721_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","volume":"107","author":"MM Chren","year":"1996","unstructured":"Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107:707\u201313.","journal-title":"J Invest Dermatol"},{"key":"1721_CR19","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archderm.1997.03890470111018","volume":"133","author":"MM Chren","year":"1997","unstructured":"Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133:1433\u201340.","journal-title":"Arch Dermatol"},{"key":"1721_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/1523-1747.ep12285650","volume":"108","author":"MM Chren","year":"1997","unstructured":"Chren MM, Lasek RJ, Quinn LM, Covinsky KE. Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life in patients with skin disease. J Invest Dermatol. 1997;108:103\u20137.","journal-title":"J Invest Dermatol"},{"key":"1721_CR21","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/archderm.138.9.1221","volume":"138","author":"J De Korte","year":"2002","unstructured":"De Korte J, Mombers FMC, Sprangers MAG, Bos JD. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol. 2002;138:1221\u20137.","journal-title":"Arch Dermatol"},{"key":"1721_CR22","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jaad.2019.12.070","volume":"83","author":"EJ Kim","year":"2020","unstructured":"Kim EJ, Geskin L, Guitart J, et al. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: preliminary findings from a prospective observational study. J Am Acad Dermatol. 2020;83:928\u201330.","journal-title":"J Am Acad Dermatol"},{"key":"1721_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4103\/ijd.IJD_433_18","volume":"65","author":"R Duffy","year":"2020","unstructured":"Duffy R, Jennings T, Sahu J. Mechlorethamine gel usage in patients with mycosis fungoides in a lymphoma clinic. Indian J Dermatol. 2020;65:237\u20139.","journal-title":"Indian J Dermatol"},{"key":"1721_CR24","doi-asserted-by":"crossref","unstructured":"Querfeld C, Geskin LJ, Kim EJ, et al. (2021) Lack of systemic absorption of topical mechlorethamine gel in patients with mycosis fungoides cutaneous T-cell lymphoma. J Invest Dermatol. S0022\u2013202X(20)32402\u20137","DOI":"10.1016\/j.jid.2020.12.009"},{"issue":"119\u201324","key":"1721_CR25","first-page":"e4","volume":"21","author":"LJ Geskin","year":"2021","unstructured":"Geskin LJ, Kim EJ, Angello JT, Kim YH. Evaluating the treatment patterns of chlormethine\/mechlorethamine gel in patients with stage I\u2013IIA mycosis fungoides: by-time reanalysis of a randomized controlled phase 2 study. Clin Lymphoma Myeloma Leuk. 2021;21(119\u201324):e4.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1721_CR26","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/archderm.1984.01650480047016","volume":"120","author":"DL Ramsay","year":"1984","unstructured":"Ramsay DL, Parnes RE, Dubin N. Response of mycosis fungoides to topical chemotherapy with mechlorethamine. Arch Dermatol. 1984;120:1585\u201390.","journal-title":"Arch Dermatol"},{"key":"1721_CR27","first-page":"165","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139:165\u201373.","journal-title":"Arch Dermatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01721-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01721-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01721-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T23:47:11Z","timestamp":1672012031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01721-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1721"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01721-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"assertion":[{"value":"25 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}